Bismarck News Updates

Venous Thromboembolism (VTE) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

 Breaking News
  • No posts were found

Venous Thromboembolism (VTE) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

May 31
14:16 2021
Venous Thromboembolism (VTE) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

DelveInsight Business Research LLP
DelveInsight’s “Venous Thromboembolism – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Venous Thromboembolism, historical and forecasted epidemiology as well as the Venous Thromboembolism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Venous Thromboembolism (VTE)-Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’sVenous Thromboembolism (VTE)–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of Venous Thromboembolism (VTE), historical and forecasted epidemiology as well as the Venous Thromboembolism (VTE) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  • As per the research study, Thromboembolism has a significant impact on morbidity and mortality internationally. A multinational report of European Union countries estimated that the total number of symptomatic, nonfatal VTE events per annum was more than 465,000 cases of DVT and more than 295,000 cases of PE.

  • Incidence found that 16,096 and 24,538 individuals in Japan were diagnosed with new PE and DVT, respectively, during 2011, which represented overall annual incidences of 12.6 and 19.2 per 100,000, respectively.

  • According to the research study incidence of first-time symptomatic VTE directly standardized for age and sex to the United States population ranged from 71 to 117 cases per 100,000 population. Approximately one-third of patients with symptomatic VTE manifest pulmonary embolism (PE), whereas two-thirds manifest deep vein thrombosis (DVT) alone. 

Key benefits of the report:

1.The Venous Thromboembolism (VTE) market report covers a descriptive overview and comprehensive insight of the Venous Thromboembolism (VTE) epidemiology and Venous Thromboembolism (VTE) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.The Venous Thromboembolism (VTE) market report provides insights into the current and emerging therapies.

3.Venous Thromboembolism (VTE) market report provides a global historical and forecasted market covering drug outreach in 7MM.

4.The Venous Thromboembolism (VTE) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Venous Thromboembolism (VTE) market.

Request for sample pages: https://www.delveinsight.com/sample-request/venous-thromboembolism-market

Venous Thromboembolism (VTE): Overview

Venous Thromboembolism (VTE) is a disorder that includes Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A deep vein thrombosis (DVT) occurs when a blood clot forms in a deep vein, usually in the lower leg, thigh, or pelvis. A deep vein thrombosis may occur if the flow of blood slows down in the body’s deep veins. A pulmonary embolism (PE) occurs when a clot breaks loose and travels through the bloodstream to the lungs.

The leading risk factor for VTE is long-term hospitalization, and the risk is high in patients with respiratory and circulatory system complications. The most common types of surgery associated with VTE are orthopedic surgeries, especially knee and hip replacements.

The key players involved in the Venous Thromboembolism (VTE) market:

  1. Bayer Pharmaceuticals

  2. Bristol-Myers Squibb/Janssen Pharmaceuticals

  3. Quercis Pharma

  4. Ono Pharmaceuticals

  5. Verseon Corporation

The launch of the emerging therapies is expected to significantly impact the  Venous Thromboembolism (VTE) treatment scenario in the upcoming years:-

Drug covered

  1. Osocimab (BAY 1213790)

  2. Milvexian (JNJ-70033093; BMS-986177)

  3. Isoquercetin

  4. ONO-7684

  5. VE-1902

Request a free sample report @ https://www.delveinsight.com/sample-request/venous-thromboembolism-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Venous Thromboembolism (VTE) Patient Share (%) Overview at a Glance

5. Venous Thromboembolism (VTE) Market Overview at a Glance

6. Venous Thromboembolism (VTE) Disease Background and Overview

7. Venous Thromboembolism (VTE) Epidemiology and Patient Population

8. Country-Specific Patient Population of Venous Thromboembolism (VTE) 

9. Venous Thromboembolism (VTE) Current Treatment and Medical Practices

10. Unmet Needs

11. Venous Thromboembolism (VTE) Emerging Therapies

12. Venous Thromboembolism (VTE) Market Outlook

13. Country-Wise Venous Thromboembolism (VTE) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Venous Thromboembolism (VTE) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Venous Thromboembolism (VTE)-Pipeline Insights, 2021

Venous Thromboembolism (VTE)-Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Venous Thromboembolism (VTE) market. A detailed picture of the Venous Thromboembolism (VTE) pipeline landscape is provided, which includes the disease overview and Venous Thromboembolism (VTE) treatment guidelines.

Venous Thromboembolism (VTE)-Epidemiology Forecast to 2030

DelveInsight’s ‘Venous Thromboembolism (VTE)-Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Venous Thromboembolism (VTE){;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Categories